Anterior Ischemic Optic Neuropathy
7
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
14.3%
1 terminated out of 7 trials
66.7%
-19.8% vs benchmark
14%
1 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
Visual Involvement in Giant Cell Arteritis
Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Effect of EECP on Anterior Ischemic Optic Neuropathy
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%